Characteristics of murine leukemias initiated by PML-RARA or PML-RARA and cooperating mutations
. | Cooperating mutations . | . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|
| Parameter . | None . | BCL2 . | FLT3 . | IL3R . | IL3 . | ||||
| Leukemia, % | 64 | 100 | 70 | 100 | 100 | ||||
| Median latency, d | 257 | 127 | 105 | 49 | 14-21 | ||||
| Disease | AML | AML | AML | AML | AML* | ||||
| Leukocytosis | No | No | Yes | Yes | Yes | ||||
| Anemia | Yes | Yes | Yes | Yes | Yes | ||||
| Thrombocytopenia | Yes | Yes | Yes | Yes | Yes | ||||
| Disseminated disease | Yes | Yes | Yes | Yes | Yes | ||||
| Transplantable | Yes | Yes | Yes | Yes | No | ||||
| ATRA response | Yes | Yes | Yes | Yes | Yes | ||||
| SKY analysis | |||||||||
| No. cases | 11 | 8 | 7 | 9 | 6 | ||||
| Abnormal (%) | 10 (91) | 8 (100) | 7 (100) | 7 (78) | 1 (17)† | ||||
| Karyotype complexity | Intermediate | Complex | Simple | Simple | Normal | ||||
| Numeric abnormality (%) | 10 (91) | 8 (100) | 7 (100) | 7 (78) | 0 | ||||
| Structural Abnormality (%) | 2 (18) | 1 (13) | 0 | 0 | 1 (17)† | ||||
| Recurring abnormalities (%) | |||||||||
| +4 | 1 (9) | 7 (88) | 0 | 0 | 0 | ||||
| +6 | 1 (9) | 4 (50) | 0 | 0 | 0 | ||||
| +7 | 1 (9) | 7 (88) | 0 | 0 | 0 | ||||
| +8 | 5 (45) | 5 (63) | 2 (29) | 7 (78) | 0 | ||||
| +10 | 3 (27) | 6 (75) | 3 (43) | 1 (11) | 0 | ||||
| +14 | 3 (27) | 5 (63) | 0 | 0 | 0 | ||||
| +15 | 7 (64) | 8 (100) | 3 (43) | 2 (22) | 0 | ||||
| +16 | 4 (36) | 3 (38) | 0 | 0 | 0 | ||||
| -X/-Y | 6 (55) | 6 (75) | 6 (86) | 4 (44) | 0 | ||||
. | Cooperating mutations . | . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|
| Parameter . | None . | BCL2 . | FLT3 . | IL3R . | IL3 . | ||||
| Leukemia, % | 64 | 100 | 70 | 100 | 100 | ||||
| Median latency, d | 257 | 127 | 105 | 49 | 14-21 | ||||
| Disease | AML | AML | AML | AML | AML* | ||||
| Leukocytosis | No | No | Yes | Yes | Yes | ||||
| Anemia | Yes | Yes | Yes | Yes | Yes | ||||
| Thrombocytopenia | Yes | Yes | Yes | Yes | Yes | ||||
| Disseminated disease | Yes | Yes | Yes | Yes | Yes | ||||
| Transplantable | Yes | Yes | Yes | Yes | No | ||||
| ATRA response | Yes | Yes | Yes | Yes | Yes | ||||
| SKY analysis | |||||||||
| No. cases | 11 | 8 | 7 | 9 | 6 | ||||
| Abnormal (%) | 10 (91) | 8 (100) | 7 (100) | 7 (78) | 1 (17)† | ||||
| Karyotype complexity | Intermediate | Complex | Simple | Simple | Normal | ||||
| Numeric abnormality (%) | 10 (91) | 8 (100) | 7 (100) | 7 (78) | 0 | ||||
| Structural Abnormality (%) | 2 (18) | 1 (13) | 0 | 0 | 1 (17)† | ||||
| Recurring abnormalities (%) | |||||||||
| +4 | 1 (9) | 7 (88) | 0 | 0 | 0 | ||||
| +6 | 1 (9) | 4 (50) | 0 | 0 | 0 | ||||
| +7 | 1 (9) | 7 (88) | 0 | 0 | 0 | ||||
| +8 | 5 (45) | 5 (63) | 2 (29) | 7 (78) | 0 | ||||
| +10 | 3 (27) | 6 (75) | 3 (43) | 1 (11) | 0 | ||||
| +14 | 3 (27) | 5 (63) | 0 | 0 | 0 | ||||
| +15 | 7 (64) | 8 (100) | 3 (43) | 2 (22) | 0 | ||||
| +16 | 4 (36) | 3 (38) | 0 | 0 | 0 | ||||
| -X/-Y | 6 (55) | 6 (75) | 6 (86) | 4 (44) | 0 | ||||